The generation of human or humanized antibodies to human antigens is of particular interest to biomedical and pharmaceutical industry for the treatment of a variety of diseases. Creative Biolabs is pleased to present world-leading de novo human/humanized antibody sequencing services. Scientists from Creative Biolabs has developed the advanced de novo antibody sequencing technology Database Assisted Shotgun Sequencing (DASS), which is an analytical method that derives an antibody’s amino acid sequence from its tandem mass spectra (MS/MS) with the assistance of a sequence database. It is in contrast to the traditional peptide identifying approach - ‘database search’, which searches in a given database to find the target peptide and is not suitable for the ‘novel’ peptide sequences.
Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarities to natural antibody variants in humans. Humanization can be necessary when the process of developing a specific antibody involves generation of the antibody in the non-human immune system. There have been four stages during the development of monoclonal antibodies as therapeutic agents, which are full murine antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies. Humanized antibodies are distinct from chimeric antibodies. Although the creation of an antibody chimera is normally performed to acquire a more human-like antibody, simple chimeras, conjugates of non-human antibody variable regions and human antibody constant regions, are not usually referred to as humanized antibodies. Rather, the protein sequence of a humanized antibody is essentially identical to that of a human variant, except that of the CDR regions responsible for the binding specificity of the antibody to its target antigen.
Fig. 1 Schematic illustration of the four stages of the development of monoclonal antibodies as therapeutic agents, which are mouse, chimeric, humanized and human monoclonal antibodies (in the anticlockwise order from the top left).
Generally, humanization is employed for the development and exploitation of therapeutic antibody products suitable for humans. Currently, human/humanized antibodies have been applied for the diagnosis and treatment of a series of human diseases, mainly including cancer, autoimmune diseases, cardiovascular diseases, graft rejection and infectious diseases. Human/humanized antibodies have become the development tendency in the global monoclonal antibody market. As the transgenic technologies and a series of display technologies developing, the proportion of human/humanized antibodies in the market is increasing. For the efficient diagnosis and therapy of diverse diseases, it is essential to obtain human/humanized therapeutic antibodies with high affinity and specificity. One of the key steps during the development of human/humanized therapeutic antibodies is to acquire the precise sequence information of the antibodies. Creative Biolabs provides de novo human/humanized antibody sequencing services with full-length coverage and 100% accuracy to fulfill our customer's requirements. A clear advantage of the de novo sequencing from Creative Biolabs based on our most advanced DASS technology is that it works for both the existing database and novel peptides. This is critically important for samples such as antibodies, which harbor hypervariable regions.